Stephanie Okey Sells 6,333 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) Director Stephanie Okey sold 6,333 shares of the company’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $63.38, for a total transaction of $401,385.54. Following the sale, the director directly owned 8,000 shares of the company’s stock, valued at approximately $507,040. This represents a 44.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

PTC Therapeutics Price Performance

Shares of PTC Therapeutics stock opened at $68.56 on Wednesday. The company’s fifty day simple moving average is $72.44 and its 200-day simple moving average is $69.72. The stock has a market capitalization of $5.68 billion, a PE ratio of 8.86 and a beta of 0.51. PTC Therapeutics, Inc. has a 1-year low of $35.95 and a 1-year high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.67) EPS for the quarter, missing the consensus estimate of ($0.21) by ($1.46). PTC Therapeutics had a negative return on equity of 362.45% and a net margin of 39.44%.The company had revenue of $164.68 million during the quarter, compared to analysts’ expectations of $281.45 million. During the same quarter last year, the company earned ($0.85) earnings per share. The company’s revenue for the quarter was down 22.7% on a year-over-year basis. As a group, research analysts anticipate that PTC Therapeutics, Inc. will post -4.52 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Barclays reaffirmed an “overweight” rating and issued a $120.00 price objective on shares of PTC Therapeutics in a research note on Monday, February 23rd. Morgan Stanley increased their target price on shares of PTC Therapeutics from $90.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday, February 23rd. Royal Bank Of Canada decreased their target price on shares of PTC Therapeutics from $87.00 to $82.00 and set a “sector perform” rating on the stock in a research note on Friday, February 20th. TD Cowen reaffirmed a “hold” rating on shares of PTC Therapeutics in a report on Thursday, January 29th. Finally, Bank of America reduced their price objective on shares of PTC Therapeutics from $97.00 to $93.00 and set a “buy” rating for the company in a research note on Friday, February 20th. Ten research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, PTC Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $82.79.

Key Headlines Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Management presented at the Leerink Global Healthcare Conference (transcript available) — the investor call/transcript gave investors fresh commentary on the pipeline and commercial progress that likely supported buying interest today. Leerink Presentation Transcript
• Positive Sentiment: Analyst support has been mixed but includes notable upside: Morgan Stanley raised its price target and Barclays reiterated an overweight with a high target — analysts’ higher targets and the stock’s consensus “Moderate Buy” help underpin the rally. MarketBeat PTCT Analyst Summary
• Neutral Sentiment: Technical/valuation context — PTCT is trading near its 200‑day average with a low beta and an attractive reported P/E (~8–9) versus peers; these factors can attract value and income‑oriented buyers even after recent volatility. MarketBeat PTCT Data
• Negative Sentiment: Several insiders sold stock on March 5 (EVP Lee Scott Golden sold 10,000 shares; Director Stephanie Okey sold 6,333; and Neil Gregory Almstead sold 3,989), which may concern some investors about insider conviction even if filings show routine dispositions. SEC filings and reporting on these sales are available here. InsiderTrades Report AmericanBankingNews
• Negative Sentiment: Recent quarterly results (Feb. 19) were a material downside surprise — EPS and revenue missed consensus and revenue declined year‑over‑year — a continuing execution/volume risk that keeps some analysts cautious. MarketBeat PTCT Earnings Summary

Institutional Trading of PTC Therapeutics

Institutional investors have recently made changes to their positions in the business. UMB Bank n.a. bought a new stake in PTC Therapeutics during the 4th quarter valued at approximately $26,000. Smartleaf Asset Management LLC boosted its stake in PTC Therapeutics by 101.3% in the 3rd quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 236 shares during the period. Optiver Holding B.V. grew its holdings in PTC Therapeutics by 96.5% during the 3rd quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 249 shares in the last quarter. Comerica Bank grew its holdings in PTC Therapeutics by 868.5% during the 3rd quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 469 shares in the last quarter. Finally, Salomon & Ludwin LLC bought a new stake in shares of PTC Therapeutics during the fourth quarter valued at approximately $41,000.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.